COQ2 nephropathy: a treatable cause of nephrotic syndrome in children
Background Nephrotic syndrome can be caused by a subgroup of mitochondrial diseases classified as primary coenzyme Q 10 (CoQ 10 ) deficiency. Pathogenic COQ2 variants are a cause of primary CoQ 10 deficiency and present with phenotypes ranging from isolated nephrotic syndrome to fatal multisystem di...
Gespeichert in:
Veröffentlicht in: | Pediatric nephrology (Berlin, West) West), 2018-07, Vol.33 (7), p.1257-1261 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Nephrotic syndrome can be caused by a subgroup of mitochondrial diseases classified as primary coenzyme Q
10
(CoQ
10
) deficiency. Pathogenic
COQ2
variants are a cause of primary CoQ
10
deficiency and present with phenotypes ranging from isolated nephrotic syndrome to fatal multisystem disease.
Case-Diagnosis/Treatment
We report three pediatric patients with
COQ2
variants presenting with nephrotic syndrome. Two of these patients had normal leukocyte CoQ
10
levels prior to treatment. Pathologic findings varied from mesangial sclerosis to focal segmental glomerulosclerosis, with all patients having abnormal appearing mitochondria on kidney biopsy. In two of the three patients treated with CoQ
10
supplementation, the nephrotic syndrome resolved; and at follow-up, both have normal renal function and stable proteinuria.
Conclusions
COQ2 nephropathy should be suspected in patients presenting with nephrotic syndrome, although less common than disease due to mutations in
NPHS1
,
NPHS2
, and
WT1
. The index of suspicion should remain high, and we suggest that providers consider genetic evaluation even in patients with normal leukocyte CoQ
10
levels, as levels may be within normal range even with significant clinical disease. Early molecular diagnosis and specific treatment are essential in the management of this severe yet treatable condition. |
---|---|
ISSN: | 0931-041X 1432-198X |
DOI: | 10.1007/s00467-018-3937-z |